Page 1

NEWS DETAILS Immunome Reports Second Quarter 2021 Financial Results 08/19/2021 EXTON , Pa .- ( BUSINESS WIRE ) – Immunome , Inc. ( Nasdaq : IMNM ) , a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first - in - class antibody therapeutics , today reported financial results for the second quarter ended June 30 , 2021 and provided a corporate update . " We made strong progress during Q2 in the development of IMM - BCP - 01 , our antibody cocktail to combat SARS - CoV - 2 . We finalized the selection of antibodies for the cocktail , secured increased funding for the program from the Department of Defense , and demonstrated IMM - BCP - 01's potent neutralization activity against all SARS - CoV - 2 variants of concern , including the Delta variant , in preclinical testing . We believe we are well - positioned for an IND filing for this program in the third quarter , " said Purnanand Sarma , Ph.D. , President and CEO of Immunome . " We have continued to strengthen the company through a number of executive and non - executive appointments , in addition to a successful fundraising . We believe these activities set us up for value - creating events in the near- term , including a planned IND filing for our IL - 38 immuno - oncology program in the fourth quarter . I look forward to updating you further on our progress in the coming months . " Second Quarter and Subsequent Highlights • Demonstrated Potent Neutralization Activity of IMM - BCP - 01 Against SARS - CoV - 2 Delta Variant . In July 2021 , Immunome announced that its three - antibody cocktail ( IMM - BCP - 01 ) has demonstrated potent neutralizing activity against the SARS - CoV - 2 Delta variant in pre-